Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 118

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells

Masciarelli, S, Fontemaggi, G, Di Agostino, S, Donzelli, S, Carcarino, E, Strano, S, Blandino, G·2014·Oncogene

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2013.106

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 53

  1. Hainaut P, Hollstein M . P53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81–137. · DOI · Paper page
  2. Oren M . Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431–442. · DOI · Paper page
  3. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811–814. · DOI · Paper page
  4. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L . Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029–1034. · DOI · Paper page
  5. Blandino G, Levine AJ, Oren M . Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477–485. · DOI · Paper page
  6. Lu C, El-Deiry WS . Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009; 14: 597–606. · DOI
  7. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16: 3269–3277. · DOI
  8. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001; 20: 4163–4172. · DOI
  9. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277: 18817–18826. · DOI · Paper page
  10. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275: 29503–29512. · DOI · Paper page
  11. Chicas A, Molina P, Bargonetti J . Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000; 279: 383–390. · DOI
  12. Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009; 16: 1086–1093. · DOI · Paper page
  13. Gohler T, Jager S, Warnecke G, Yasuda H, Kim E, Deppert W . Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005; 33: 1087–1100. · DOI
  14. Israel A, Sharan R, Ruppin E, Galun E . Increased microRNA activity in human cancers. PLoS One 2009; 4: e6045. · DOI
  15. Wang L, Wang J . MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2011; 31: 2499–2511. · DOI
  16. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2011; 19: 1038–1048. · DOI
  17. Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev 2006; 6: 857–866. · DOI · Paper page
  18. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129: 617–631. · DOI · Paper page
  19. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819–831. · DOI · Paper page
  20. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820–5828. · DOI · Paper page
  21. Haddad Y, Choi W, McConkey DJ . Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009; 15: 532–542. · DOI
  22. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE . Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629–3637. · DOI · Paper page
  23. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944–950. · DOI · Paper page
  24. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 2001; 21: 8461–8470. · DOI
  25. Mueller PR, Coleman TR, Kumagai A, Dunphy WG . Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science (New York) 1995; 270: 86–90. · DOI · Paper page
  26. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768–1778. · DOI · Paper page
  27. Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35. · DOI · Paper page
  28. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387–392. · DOI · Paper page
  29. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135: 257–269. · DOI · Paper page
  30. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL et al. MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One 2011; 6: e27008. · DOI
  31. Rubin CI, Atweh GF . The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004; 93: 242–250. · DOI · Paper page
  32. Melhem RF, Strahler JR, Hailat N, Zhu XX, Hanash SM . Involvement of OP18 in cell proliferation. Biochem Biophys Res Commun 1991; 179: 1649–1655. · DOI
  33. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R et al. P53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 2000; 88: 685–691. · doi:10.1002/1097-0215(20001201)88:5<685::aid-ijc1>3.0.co;2-z
  34. Mistry SJ, Li HC, Atweh GF . Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin. Biochem J 1998; 334 (Part 1): 23–29. · DOI
  35. Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2009; 117: 183–191. · DOI
  36. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008; 14: 435–445. · DOI
  37. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brunner N et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008; 110: 317–326. · DOI
  38. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106: 4834–4839. · DOI · Paper page
  39. Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010; 9: 4897–4905. · doi:10.1021/pr100712t
  40. Belletti B, Baldassarre G . Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Therap Targets 2011; 15: 1249–1266. · DOI · Paper page
  41. Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C et al. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol 2011; 30: 715–726. · DOI
  42. Rana S, Maples PB, Senzer N, Nemunaitis J . Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008; 8: 1461–1470. · DOI
  43. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL . Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999; 18: 5954–5958. · DOI
  44. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490–2501. · DOI · Paper page
  45. Alli E, Bash-Babula J, Yang JM, Hait WN . Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 6864–6869.
  46. Alli E, Yang JM, Hait WN . Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003–1012. · DOI
  47. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (Baltimore, MD) 2007; 46: 759–768. · DOI
  48. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012; 7: e33919. · doi:10.1371/journal.pone.0033919
  49. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P et al. p27(Kip1)–stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7: 51–63. · DOI · Paper page
  50. Manceau V, Gavet O, Curmi P, Sobel A . Stathmin interaction with HSC70 family proteins. Electrophoresis 1999; 20: 409–417. · doi:10.1002/(sici)1522-2683(19990201)20:2<409::aid-elps409>3.0.co;2-n
  51. Maucuer A, Camonis JH, Sobel A . Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. Proc Natl Acad Sci USA 1995; 92: 3100–3104. · DOI
  52. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006; 172: 245–257. · DOI · Paper page
  53. Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci USA 2008; 105: 11299–11304. · DOI · Paper page

Cited by

See all 118

Metadata

Authors
Masciarelli, S., Fontemaggi, G., Di Agostino, S., Donzelli, S., Carcarino, E., Strano, S., & Blandino, G.
Venue
Oncogene
Published
2013-04-15
Volume
33
Issue
12
Pages
1601-1608
ISSN
  • 0950-9232
  • 1476-5594
Cited by
118
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. https://app.cochat.ai/papers/10.1038/onc.2013.106
The paper
Masciarelli, S., Fontemaggi, G., Di Agostino, S., Donzelli, S., Carcarino, E., Strano, S., & Blandino, G. (2014). Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene. https://doi.org/10.1038/onc.2013.106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.